Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 12, 2016 5:14 AM ET

Biotechnology

Company Overview of Bird Rock Bio, Inc.

Company Overview

Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of novel immune-inflammatory regulators. It offers novel biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis, and nonalcoholic steatohepatitis. The company’s technology enables the company to leverage biologic therapeutic specificity across a set of targets from a family of proteins, the G-protein coupled receptor (GPCR) protein family, where specificity in binding is important. It develops novel antibodies with upsized potential that represent antibody therapeutics to GPCR targets validated with small molecules; and antibody therapeutics to validated targets for ...

505 Coast Boulevard

Suite 300

La Jolla, CA 92037

United States

Founded in 2006

Phone:

858-587-4815

Fax:

858-587-4854

Key Executives for Bird Rock Bio, Inc.

Chief Executive Officer, President and Director
Chief Financial Officer
Age: 45
Senior Vice President of Research & Development, Bology & Pharmacology
Vice President of Business Development
Vice President of Translational Research
Compensation as of Fiscal Year 2015.

Bird Rock Bio, Inc. Key Developments

RuiYi Doses First Patient in Double-Blinded Trial of Gerilimzumab to Treat Arthritis

RuiYi has dosed first patient with Gerilimzumab novel monoclonal antibody to treat rheumatoid arthritis (RA) and other autoimmune disorders. Gerilimzumab is directed against the IL-6 cytokine. The double-blinded and placebo controlled trial includes single and multiple ascending dose cohorts. RuiYi plans to release the trial's results in the first quarter of 2015 and advance Gerilimzumab into further studies, including in moderate to severe RA.

RuiYi Inc. Presents at 14th Annual BIO Investor Forum, Oct-21-2015 10:30 AM

RuiYi Inc. Presents at 14th Annual BIO Investor Forum, Oct-21-2015 10:30 AM. Venue: Parc 55 Hotel, San Francisco, California, United States.

RuiYi Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 03:00 PM

RuiYi Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 03:00 PM. Venue: The Palace Hotel, San Francisco, CA 94105, United States.

Similar Private Companies By Industry

Company Name Region
LaserGen, Inc. United States
Regulon Inc. United States
Echelon Biosciences Incorporated United States
Rhythm Therapeutics, Inc. United States
ImmuMetrix, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
January 25, 2016
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Bird Rock Bio, Inc., please visit www.birdrockbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.